Paladin Assumes All Canadian Marketing Of Nuvo’s Pennsaid
This article was originally published in The Pink Sheet Daily
Executive Summary
Montreal company will now receive all revenues from osteoarthritis agent after acquiring rights from Nuvo’s promotional partner Solvay.
You may also be interested in...
Nuvo's Pennsaid “Approvable” For Osteoarthritis
Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.
Nuvo's Pennsaid “Approvable” For Osteoarthritis
Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.
Pennsaid Amended NDA Has Mid-December User Fee Date
Nuvo’s Class 2 resubmission includes data from a Phase III efficacy trial and single-arm, long-term safety study.